A consumer-safety comparison published this week walks through the practical differences between Wegovy and Ozempic, the two Novo Nordisk brands built on the same active molecule, semaglutide. The distinction matters far beyond the pharmacy counter: when two of the most counterfeited drugs in the world share one molecule but not one label, confusion about what is actually in the vial becomes a supply-chain problem — and the gray market for bulk semaglutide exploits exactly that gap.
What Happened
The analysis lays out that although both products contain semaglutide, regulators approved them for different indications and different maximum strengths. Ozempic is approved to treat Type 2 diabetes and to prevent major cardiovascular events in certain patients. Wegovy is approved for chronic weight management in adults with obesity — or overweight plus a metabolic comorbidity — and to reduce the risk of cardiovascular death, heart attack, and stroke in patients with overweight or obesity.
Clinicians contributing to the comparison note that because the brands share an active ingredient, they share a side-effect profile. The higher approved Wegovy dose can make side effects more pronounced, and a meaningful share of patients — cited at up to 10 percent — discontinue because side effects do not resolve. The piece also reiterates that recurring global supply shortages have affected both brands, and that off-label prescribing decisions belong with a knowledgeable clinician, not with the buyer.
Who Is Affected
- Patients and researchers who treat every semaglutide product as interchangeable, despite different approved uses
- Clinicians fielding off-label requests driven by brand-name familiarity
- Gray-market buyers, who face the sharpest version of the problem: bulk semaglutide sold through research-chemical channels carries no brand label, no indication, and no approved dose at all
- Compounders and counterfeiters, for whom brand confusion is the business model
Timeline
- December 2017 — FDA approves Ozempic (semaglutide) for Type 2 diabetes
- January 2020 — Ozempic gains a cardiovascular indication for diabetic patients with heart disease
- June 2021 — FDA approves Wegovy for chronic weight management
- March 2024 — Wegovy gains its own cardiovascular indication for adults with overweight or obesity and established cardiovascular disease
- 2022 onward — recurring shortages of both brands fuel compounded and counterfeit semaglutide trade worldwide
What This Means for Researchers
The comparison underscores a pattern PepsReview has tracked across enforcement actions: brand-name trust does not transfer to unlabeled product. A gray-market listing that says only semaglutide tells you nothing about purity, sterility, endotoxin load, or whether the vial contains the compound at all. FDA warning letters to ingredient suppliers, seizures of counterfeit pens, and criminal cases involving mislabeled bulk peptide all trace back to the same gap — a buyer who stopped asking which product, which indication, and which dose they were actually purchasing.
How to Verify Your Peptides
Safe Alternatives
Sources
Industry reports; regulatory announcements.